Q3 FY2026 · ended Sep 30, 2026 · Revenue $0 · Filed Nov 6, 2026
Entera Bio Ltd. (ENTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $15.6 million. Free cash flow was -$7.4 million. As of Sep 30, 2026 it held $265.9 million in cash and investments and $397,000 in total debt.
Revenue
$0
Net income
$-15.60M
-387.4% vs year-ago quarter
Operating cash flow
$-7.40M
-195.7% vs year-ago quarter
Free cash flow
$-7.42M
-191.6% vs year-ago quarter
EPS
$0.11
+57.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
174.14M
+279.7% vs year-ago quarter
Net cash
$265.49M
Q3 FY2026
Operating margin
-6102.4%
Q1 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Jerusalem
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638097
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.3M | -$4.6M | -$3.5M | -$3.0M | -$3.3M |
| Net income | -$15.6M | -$7.3M | -$3.5M | -$3.0M | -$3.2M |
| Diluted EPS | $0.11 | $0.14 | $0.07 | -$0.06 | $0.07 |
| Operating cash flow | -$7.4M | -$3.5M | -$3.1M | -$1.8M | -$2.5M |
| Free cash flow | -$7.4M | -$3.5M | -$3.1M | -$1.9M | -$2.5M |
| Total assets | $277.0M | $19.5M | $13.1M | $16.0M | $17.4M |
| Total liabilities | $2.8M | $12.2M | $2.4M | $2.9M | $2.2M |
| Stockholders' equity | $274.3M | $7.3M | $10.7M | $13.1M | $15.2M |
| Cash and investments | $265.9M | $11.3M | $4.1M | $7.1M | $8.6M |
| Total debt | $397,000 | $425,000 | $448,000 | $490,000 | $211,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Jul 28, 2026 | Jul 26, 2026 |
All 418 Entera Bio Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.